Atomistic molecular dynamics simulations of typical and atypical antipsychotic drugs at the dopamine D2 receptor (D2R) elucidates their inhibition mechanism

References

• Ablordeppey, S. Y., Altundas, R., Bricker, B., Zhu, X. Y., Kumar, E. V. K. S., Jackson, T., … Roth, B. L. (2008). Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-Chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one. Bioorganic & Medicinal Chemistry, 16, 7291–7301.
   PubMed Web of Science ®Google Scholar
• Apweiler, R. (2009). The universal protein resource (UniProt) in 2010. Nucleic Acids Research, 38, D142–D148. doi: 10.1093/nar/gkp84.
   Google Scholar
• Arinami, T., Gao, M., Hamaguchi, H., & Toru, M. (1997). A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Human Molecular Genetics, 6, 577–582. doi:10.1093/hmg/6.4.577
   PubMed Web of Science ®Google Scholar
• Bas, D. C., Rogers, D. M., & Jensen, J. H. (2008). Very fast prediction and rationalization of pKa values for protein–ligand complexes. Proteins: Structure, Function and Genetics, 73, 765–783. doi:10.1002/prot.22102
   PubMed Web of Science ®Google Scholar
• Borroto-Escuela, D. O., Romero-Fernandez, W., Narvaez, M., Oflijan, J., Agnati, L. F., & Fuxe, K. (2014). Hallucinogenic 5-HT2AR agonists LSD and DOI enhance dopamine D2R protomer recognition and signaling of D2-5-HT2A heteroreceptor complexes. Biochemical and Biophysical Research Communications, 443, 278–284. doi:10.1016/j.bbrc.2013.11.104
   PubMed Web of Science ®Google Scholar
• Bussi, G., & Parrinello, M. (2007). Accurate sampling using Langevin dynamics. Physical Review E – Statistical, Nonlinear, and Soft Matter Physics, 75(5), 1–7. doi:10.1103/PhysRevE.75.056707
   Web of Science ®Google Scholar
• Chien, E. Y. T., Liu, W., Zhao, Q., Katritch, V., Han, G. W., Hanson, M. A., … Stevens, R. C. (2010). Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Science, 330, 1091–1095. doi:10.1126/science.1197410
   PubMed Web of Science ®Google Scholar
• Christopoulos, A., & Kenakin, T. (2002). G protein-coupled receptor allosterism and complexing. Pharmacological Reviews, 54, 323–374. doi:10.1124/pr.54.2.323
   PubMed Web of Science ®Google Scholar
• Conn, P. J., Christopoulos, A., & Lindsley, C. W. (2009). Allosteric modulators of GPCRs: A novel approach for the treatment of CNS disorders. Nature Reviews. Drug Discovery, 8, 41–54. doi:10.1038/nrd2760
   PubMed Web of Science ®Google Scholar
• Darden, T., York, D., & Pedersen, L. (1993). Particle mesh Ewald: An N log(N) method for Ewald sums in large systems. The Journal of Chemical Physics, 98, 10089–10092. doi:10.1063/1.464397
   Web of Science ®Google Scholar
• Desmond Molecular Dynamics System. 2009 (Version 2.2). New York, NY: D.E. Shaw Research.
   Google Scholar
• Dijkstra, D., Rodenhuis, N., Vermeulen, E. S., Pugsley, T. A., Wise, L. D., & Wikström, H. V. (2002). Further characterization of structural requirements for ligands at the dopamine D(2) and D(3) receptor: Exploring the thiophene moiety. Journal of Medicinal Chemistry, 45, 3022–3031.10.1021/jm001015a
   PubMed Web of Science ®Google Scholar
• Dilly, S., & Liégeois, J.-F. (2011). Interaction of clozapine and its nitrenium ion with rat D2 dopamine receptors: In vitro binding and computational study. Journal of Computer-Aided Molecular Design, 25, 163–169. doi:10.1007/s10822-010-9407-8
   PubMed Web of Science ®Google Scholar
• Durdagi, S., Papadopoulos, M. G., Zoumpoulakis, P. G., Koukoulitsa, C., & Mavromoustakos, T. (2010). A computational study on cannabinoid receptors and potent bioactive cannabinoid ligands: homology modeling, docking, de novo drug design and molecular dynamics analysis. Molecular Diversity, 14, 257–276.
   PubMed Web of Science ®Google Scholar
• Durdagi, S., Salmas, R. E., Stein, M., Yurtsever, M., & Seeman, P. (2015). Binding interactions of dopamine and apomorphine in D2High and D2Low states of human dopamine D2 receptor (D2R) using computational and experimental techniques. ACS Chemical Neuroscience, 17 ,185–195. doi:10.1021/acschemneuro
   Google Scholar
• Durdagi, S., Subbotina, J., Lees-Miller, J., Guo, J., Duff, H. J., & Noskov, S. Y. (2010). Insights into the molecular mechanism of hERG1 channel activation and blockade by drugs. Current Medicinal Chemistry, 17, 3514–3532.
   PubMed Web of Science ®Google Scholar
• Ekhteiari Salmas, R., Mestanoglu, M., Unlu, A., Yurtsever, M., & Durdagi, S. (2016). Mutated form (G52E) of inactive diphtheria toxin CRM197: Molecular simulations clearly display effect of the mutation to NAD binding. Journal of Biomolecular Structure and Dynamics. doi:10.1080/07391102.2015.1119060.
   PubMed Web of Science ®Google Scholar
• Farid, R., Day, T., Friesner, R. A., & Pearlstein, R. A. (2006). New insights about HERG blockade obtained from protein modeling, potential energy mapping, and docking studies. Bioorganic and Medicinal Chemistry, 14, 3160–3173. doi:10.1016/j.bmc.2005.12.032
   PubMed Web of Science ®Google Scholar
• Fotakis, C., Gega, S., Siapi, E., Potamitis, C., Viras, K., Moutevelis-Minakakis, P., … Mavromoustakos, T. (2010). Interactions at the bilayer interface and receptor site induced by the novel synthetic pyrrolidinone analog MMK3. Biochimica et Biophysica Acta, 1798, 422–432.
   PubMed Web of Science ®Google Scholar
• Fuxe, K., Borroto-Escuela, D. O., Tarakanov, A. O., Romero-Fernandez, W., Ferraro, L., Tanganelli, S., … Agnati, L. F. (2014). Dopamine D2 heteroreceptor complexes and their receptor–receptor interactions in ventral striatum: Novel targets for antipsychotic drugs. Progress in Brain Research, 211, 113–139. doi:10.1016/B978-0-444-63425-2.00005-2
   Google Scholar
• Fuxe, K., Manger, P., Genedani, S., & Agnati, L. (2006). The nigrostriatal DA pathway and Parkinson’s disease. Journal of Neural Transmission. Supplementum, 70, 71–83.10.1007/978-3-211-45295-0
   PubMedGoogle Scholar
• Greengard, P. (2001). The neurobiology of dopamine signaling. Bioscience Reports, 21, 247–269. doi:10.1023/A:1013205230142
   PubMed Web of Science ®Google Scholar
• Grubmüller, H., & Groll, V. (2013). Retrieved from http://www.mpibpc.mpg.de/home/grubmueller/downloads/solvate/index.html
   Google Scholar
• Hollenstein, K., De Graaf, C., Bortolato, A., Wang, M. W., Marshall, F. H., & Stevens, R. C. (2014). Insights into the structure of class B GPCRs. Trends in Pharmacological Sciences, 35, 12–22. doi:10.1016/j.tips.2013.11.001
   PubMed Web of Science ®Google Scholar
• Hoover, W. G. (1985). Canonical dynamics: Equilibrium phase-space distributions. Physical Review A, 31, 1695–1697. doi:10.1103/PhysRevA.31.1695
   PubMed Web of Science ®Google Scholar
• Huang, J., & Mackerell, A. D. (2013). CHARMM36 all-atom additive protein force field: Validation based on comparison to NMR data. Journal of Computational Chemistry, 34, 2135–2145. doi:10.1002/jcc.23354
   PubMed Web of Science ®Google Scholar
• Humphrey, W., Dalke, A., & Schulten, K. V. M. D. (1996). VMD: Visual molecular dynamics. Journal of Molecular Graphics, 14, 33–38.10.1016/0263-7855(96)00018-5
   PubMed Web of Science ®Google Scholar
• Irwin, J. J., Sterling, T., Mysinger, M. M., Bolstad, E. S., & Coleman, R. G. (2012). ZINC: A free tool to discover chemistry for biology. Journal of Chemical Information and Modeling, 52, 1757–1768. doi:10.1021/ci3001277
   PubMed Web of Science ®Google Scholar
• Javitch, J. A., Fu, D., & Chen, J. (1995). Residues in the fifth membrane–spanning segment of the dopamine D2 receptor exposed in the binding–site crevice. Biochemistry, 34, 16433–16439. doi:10.1021/bi00050a026
   PubMed Web of Science ®Google Scholar
• Javitch, J. A. Ballesteros, J. A., Chen, J., Chiappa, V., & Simpson, M. M. (1999). Electrostatic and aromatic microdomains within the binding-site crevice of the D2 receptor: Contributions of the second membrane-spanning segment. Biochemistry, 38, 7961–7968. doi:10.1021/bi9905314
   PubMed Web of Science ®Google Scholar
• Johnson, D. S., Choi, C., Fay, L. K., Favor, D. A, Repine, J. T., White, A. D., … Serpa, K. A. (2011). Discovery of PF-00217830: Aryl piperazine napthyridinones as D2 partial agonists for schizophrenia and bipolar disorder. Bioorganic & Medicinal Chemistry Letters, 21, 2621–2625.
   PubMed Web of Science ®Google Scholar
• Kalani, M. Y. S., Vaidehi, N., Hall, S. E., Trabanino, R. J., Freddolino, P. L., Kalani, M. A., … Goddard, W. A. (2004). The predicted 3D structure of the human D2 dopamine receptor and the binding site and binding affinities for agonists and antagonists. Proceedings of the National Academy of Sciences, 101, 3815–3820. doi:10.1073/pnas.0400100101
   PubMed Web of Science ®Google Scholar
• Kemsley, E. K., & Tapp, H. S. (2009). OPLS filtered data can be obtained directly from non-orthogonalized PLS1. Journal of Chemometrics, 23(December 2008), 263–264. doi:10.1002/cem.1217
   Web of Science ®Google Scholar
• Kienast, T., & Heinz, A. (2006). Dopamine and the diseased brain. CNS & Neurological Disorders Drug Targets, 5, 109–131. doi:10.2174/187152706784111560
   PubMedGoogle Scholar
• Kling, R. C., Tschammer, N., Lanig, H., Clark, T., & Gmeiner, P. (2014). Active-state model of a dopamine D2 receptor – Gαi complex stabilized by aripiprazole-type partial agonists. PLoS One, 9, e100069. doi:10.1371/journal.pone.0100069
   Google Scholar
• Lagerström, M. C., & Schiöth, H. B. (2008). Structural diversity of G protein-coupled receptors and significance for drug discovery. Nature Reviews. Drug Discovery, 7, 339–357. doi:10.1038/nrd2518
   PubMed Web of Science ®Google Scholar
• Larkin, M., Blackshields, G., Brown, N., Chenna, R., McGettigan, P., McWilliam, H., … Higgins, D. (2007). Clustal W and Clustal X version 2.0. Bioinformatics, 23, 2947–2948. doi:10.1093/bioinformatics/btm404
   PubMed Web of Science ®Google Scholar
• Laskowski, R. A, MacArthur, M. W., Moss, D. S., & Thornton, J. M. (1993). PROCHECK: A program to check the stereochemical quality of protein structures. Journal of Applied Crystallography, 26, 283–291. doi:10.1107/S0021889892009944
   Web of Science ®Google Scholar
• Leonis, G., Avramopoulos, A., Salmas, R. E., Durdagi, S., Yurtsever, M., & Papadopoulos, M. G. (2014). Elucidation of conformational states, dynamics, and mechanism of binding in human κ-opioid receptor complexes. Journal of Chemical Information and Modeling, 54, 2294–2308. doi:10.1021/ci5002873
   PubMed Web of Science ®Google Scholar
• Leopoldo, M., Berardi, F., Colabufo, N. A., De Giorgio, P., Lacivita, E., Perrone, R., & Tortorella, V. (2002). Structure–affinity relationship study on N-[4-(4-arylpiperazin-1-yl)butyl]arylcarboxamides as potent and selective dopamine D3 receptor ligands. Journal of Medicinal Chemistry, 45, 5727–5735.10.1021/jm020952a
   PubMed Web of Science ®Google Scholar
• Lin, C. H., Haadsmasvensson, S. R., Phillips, G., Lahti, R. A., Mccall, R. B., Piercey, M. F., … Chidester, C. G. (1993). Centrally acting serotonergic and dopaminergic agents. 2. Synthesis and structure-activity relationships of 2,3,3a,4,9,9a-hexahydro-1H-benz[f]indole derivatives. Journal of Medicinal Chemistry, 36, 1069–1083.10.1021/jm00060a015
   PubMed Web of Science ®Google Scholar
• Mansour, A., Meng, F., Meador-Woodruff, J. H., Taylor, L. P., Civelli, O., & Akil, H. (1992). Site-directed mutagenesis of the human dopamine D2 receptor. European Journal of Pharmacology: Molecular Pharmacology, 227, 205–214. doi:10.1016/0922-4106(92)90129-j
   PubMed Web of Science ®Google Scholar
• Martyna, G. J., Tobias, D. J., & Klein, M. L. (1994). Constant pressure molecular dynamics algorithms. The Journal of Chemical Physics, 101, 4177–4189. doi:10.1063/1.467468
   Web of Science ®Google Scholar
• Marvin 14.12.15.0. 2014. ChemAxon. Retrieved from http://www.chemaxon.com
   Google Scholar
• McRobb, F. M., Capuano, B., Crosby, I. T., Chalmers, D. K., & Yuriev, E. (2010). Homology modeling and docking evaluation of aminergic G protein-coupled receptors. Journal of Chemical Information and Modeling, 50, 626–637. doi:10.1021/ci900444q
   PubMed Web of Science ®Google Scholar
• Miyamoto, S., & Kollman, P. A. (1992). Settle: An analytical version of the SHAKE and RATTLE algorithm for rigid water models. Journal of Computational Chemistry, 13, 952–962. doi:10.1002/jcc.540130805
   Web of Science ®Google Scholar
• Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006). How many drug targets are there? Nature Reviews Drug Discovery, 5, 993–996. doi:10.1038/nrd2199
   PubMed Web of Science ®Google Scholar
• Palczewski, K. (2000). Crystal structure of rhodopsin: A G protein-coupled receptor. Science, 289, 739–745. doi:10.1126/science.289.5480.739
   PubMed Web of Science ®Google Scholar
• Paul, M. L., Graybiel, A. M., David, J. C., & Robertson, H. A. (1992). D1-like and D2-like dopamine receptors synergistically activate rotation and c-fos expression in the dopamine-depleted striatum in a rat model of Parkinson’s disease. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 12, 3729–3742.
   PubMed Web of Science ®Google Scholar
• Phillips, J. C., Braun, R., Wang, W., Gumbart, J., Tajkhorshid, E., Villa, E., … Schulten, K. (2005). Scalable molecular dynamics with NAMD. Journal of Computational Chemistry, 26, 1781–1802. doi:10.1002/jcc.20289
   PubMed Web of Science ®Google Scholar
• Pogozheva, I. D., Lomize, M. A., Mosberg, H. I., & Lomize, A. L. (2006). OPM: Orientations of proteins in membranes database. Bioinformatics (Oxford, England), 22, 623–625. doi:10.1093/bioinformatics/btk023
   PubMed Web of Science ®Google Scholar
• Ramachandran, G. N., Ramakrishnan, C., & Sasisekharan, V. (1963). Stereochemistry of polypeptide chain configurations. Journal of Molecular Biology, 7, 95–99. doi:10.1016/S0022-2836(63)80023-6
   PubMed Web of Science ®Google Scholar
• Rasmussen, S. G. F., DeVree, B. T., Zou, Y., Kruse, A. C., Chung, K. Y., Kobilka, T. S., … Kobilka, B. K. (2011). Crystal structure of the β2 adrenergic receptor-Gs protein complex. Nature, 477, 549–555. doi:10.1038/nature10361
   PubMed Web of Science ®Google Scholar
• Rohl, C. A., Strauss, C. E. M., Misura, K. M. S., & Baker, D. (2004). Protein structure prediction using Rosetta. Methods in Enzymology, 383, 66–93. doi:10.1016/S0076-6879(04)83004-0
   PubMed Web of Science ®Google Scholar
• Rosenbaum, D. M., Rasmussen, S. G. F., & Kobilka, B. K. (2009). The structure and function of G-protein-coupled receptors. Nature, 459, 356–363. doi:10.1038/nature08144
   PubMed Web of Science ®Google Scholar
• Rowley, M., Bristow, L. J., & Hutson, P. H. (2001). Current and novel approaches to the drug treatment of schizophrenia. Journal of Medicinal Chemistry, 44, 477–501.10.1021/jm0002432
   PubMed Web of Science ®Google Scholar
• Rubenstein, L. A., & Lanzara, R. G. (1998). Activation of G protein-coupled receptors entails cysteine modulation of agonist binding. Journal of Molecular Structure: THEOCHEM, 430, 57–71. doi:10.1016/S0166-1280(98)90217-2
   Web of Science ®Google Scholar
• Salmas, R. E., Mestanoglu, M., Yurtsever, M., Noskov, S. Y., & Durdagi, S. (2015). Molecular simulations of solved co-crystallized X-ray structures identify action mechanisms of PDEδ inhibitors. Biophysical Journal, 109, 1163–1168. doi:10.1016/j.bpj.2015.08.001
   PubMed Web of Science ®Google Scholar
• Salmas, R. E., Senturk, M., Yurtsever, M., & Durdagi, S. (2015). Discovering novel carbonic anhydrase type IX (CA IX) inhibitors from seven million compounds using virtual screening and in vitro analysis. Journal of Enzyme Inhibition and Medicinal Chemistry, 6366, 1–9. doi:10.3109/14756366.2015.1036049
   Web of Science ®Google Scholar
• Salmas, R. E., Unlu, A., Yurtsever, M., Noskov, S. Y., & Durdagi, S. (2015). In silico investigation of PARP-1 catalytic domains in holo and apo states for the design of high-affinity PARP-1 inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 6366, 1–9. doi:10.3109/14756366.2015.1005011
   Web of Science ®Google Scholar
• Salmas, R. E., Yurtsever, M., & Durdagi, S. (2015). Investigation of inhibition mechanism of chemokine receptor CCR5 by micro-second molecular dynamics simulations. Scientific Reports, 5, 13180, 1–12. doi:10.1038/srep13180
   Web of Science ®Google Scholar
• Salmas, R. E., Yurtsever, M., Stein, M., Durdagi, S., & . (2015). Modeling and protein engineering studies of active and inactive states of human dopamine D2 receptor (D2R) and investigation of drug/receptor interactions. Molecular Diversity, 19, 321–332. doi:10.1007/s11030-015-9569-3
   PubMed Web of Science ®Google Scholar
• Schrödinger Release 2014-1: LigPrep. 2014. (Version 2.9). New York, NY: Schrödinger, LLC.
   Google Scholar
• Schultz, W. (2007). Multiple dopamine functions at different time courses. Annual Review of Neuroscience, 30, 259–288. doi:10.1146/annurev.neuro.28.061604.135722
   PubMed Web of Science ®Google Scholar
• Seeman, P., Chau-Wong, M., Tedesco, J., & Wong, K. (1975). Brain receptors for antipsychotic drugs and dopamine: Direct binding assays. Proceedings of the National Academy of Sciences, 72, 4376–4380. doi:10.1073/pnas.72.11.4376
   PubMed Web of Science ®Google Scholar
• Seeman, P., & Tallerico, T. (1999). Rapid release of antipsychotic drugs from dopamine D2 receptors: An explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine. American Journal of Psychiatry, 156, 876–884.10.1176/ajp.156.6.876
   PubMed Web of Science ®Google Scholar
• Siu, S. W. I., Pluhackova, K., & Böckmann, R. A (2012). Optimization of the OPLS-AA force field for long hydrocarbons. Journal of Chemical Theory and Computation, 8, 1459–1470. doi:10.1021/ct200908r
   PubMed Web of Science ®Google Scholar
• Vanommeslaeghe, K., Prabhu Raman, E., & MacKerell, A. D. J. (2012). Automation of the CHARMM general force field (CGenFF) II: Assignment of bonded parameters and partial atomic charges. Journal of Chemical Information and Modeling, 52, 3155–3168. doi:10.1021/ci300363c
   PubMed Web of Science ®Google Scholar
• Venkatakrishnan, A. J., Deupi, X., Lebon, G., Tate, C. G., Schertler, G. F., & Babu, M. M. (2013). Molecular signatures of G-protein-coupled receptors. Nature, 494, 185–194. doi:10.1038/nature11896
   PubMed Web of Science ®Google Scholar
• Wermuth, C. G. (2004). Selective optimization of side activities: Another way for drug discovery. Journal of Medicinal Chemistry, 47, 1303–1314.10.1021/jm030480f
   PubMed Web of Science ®Google Scholar
• Webb, B., & Sali, A. (2014). Comparative protein structure modeling using MODELLER. Current Protocols in Bioinformatics, 2014, 5.6.1–5.6.32. doi:10.1002/0471250953.bi0506s47
   Google Scholar
• Wettschureck, N., & Offermanns, S. (2005). Mammalian G proteins and their cell type specific functions. Physiological Reviews, 85, 1159–1204. doi:10.1152/physrev.00003.2005
   PubMed Web of Science ®Google Scholar
• Wiederstein, M., & Sippl, M. J. (2007). ProSA-web: Interactive web service for the recognition of errors in three-dimensional structures of proteins. Nucleic Acids Research, 35 (Web Server issue), W407–W410. doi:10.1093/nar/gkm290
   PubMed Web of Science ®Google Scholar
• Wise, A., Gearing, K., & Rees, S. (2002). Target validation of G-protein coupled receptors. Drug Discovery Today, 7, 235–246. doi:10.1016/S1359-6446(01)02131-6
   PubMed Web of Science ®Google Scholar
• Zeng, F. Y. Soldner, A., Schöneberg, T., & Wess, J. (1999). Conserved extracellular cysteine pair in the M3 muscarinic acetylcholine receptor is essential for proper receptor cell surface localization but not for G protein coupling. Journal of Neurochemistry, 72, 2404–2414. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/10349850
   PubMed Web of Science ®Google Scholar
• Zhang, L., & Skolnick, J. (1998). What should the Z-score of native protein structures be? Protein Science, 7, 1201–1207.10.1002/pro.v7:5
   PubMed Web of Science ®Google Scholar
• Zhang, X., Hodgetts, K., Rachwal, S., Zhao, H., Wasley, J. W. F., Craven, K., … Thurkauf, A. (2000). Trans-1-[(2-phenylcyclopropyl)methyl]-4-arylpiperazines: Mixed dopamine D2/D4 receptor antagonists as potential antipsychotic agents. Journal of Medicinal Chemistry, 43, 3923–3932.10.1021/jm990562x
   PubMed Web of Science ®Google Scholar